Trials / Active Not Recruiting
Active Not RecruitingNCT06095115
A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Retreatment
- Status
- Active Not Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 684 (actual)
- Sponsor
- Janssen Research & Development, LLC · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is see how effective is JNJ-77242113 in participants with moderate to severe plaque psoriasis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | JNJ-77242113 | JNJ-77242113 will be administered orally. |
| DRUG | Placebo | Placebo will be administered orally |
Timeline
- Start date
- 2023-10-12
- Primary completion
- 2024-07-29
- Completion
- 2027-04-06
- First posted
- 2023-10-23
- Last updated
- 2026-04-13
Locations
170 sites across 16 countries: United States, Argentina, Australia, Canada, China, France, Germany, Hungary, Italy, Japan, Poland, South Korea, Spain, Taiwan, Turkey (Türkiye), United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06095115. Inclusion in this directory is not an endorsement.